VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Bristol Myers Squibb Unveils Positive Phase 3 Data for Next-Gen CELMoD Mezigdomide in Relapsed/Refractory Multiple Myeloma
Bristol Myers Squibb Unveils Positive Phase 3 Data for Next-Gen CELMoD Mezigdomide in Relapsed/Refractory Multiple Myeloma
May 29, 2026 16:17 CST Updated May 30, 04:55
Share:
